SWOG clinical trial number
S9912
Phase II Evaluation of Intravenous Paclitaxel, Intraperitoneal Cisplatin, Intravenous Liposomal Doxorubicin and Intraperitoneal Paclitaxel in Women with Optimally-Debulked Stage III Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Closed
Phase
Accrual
100%
Published
Research committees
Gynecologic Cancer
Treatment
Cisplatin
Paclitaxel
Liposomal Doxorubicin
Surgery
Eligibility Criteria Expand/Collapse
Histological confirmation of epithelial ovarian, primary peritoneal or fallopian tube cancer. Mixed mullerian tumors allowed. Exploratory laparotomy with tumor debulking and FIGO Stage III at initial Laparotomy. The pts are eligible if at the time of surgical staging, a Grade I Stage IA or IB endometrial carcinoma is incidentally found. Must be registered within 70 days of staging laparotomy. Performance status of 0 - 1 by Southwest Oncology Group criteria. No prior chemotherapy, immunotherapy or pelvic radiation for ovarian ca. No clinical evidence of residual disease by physical examination and chest x-ray within 28 days to registration. No gastrointestinal symptoms. Must have specimens available for pathology review. No concurrent antitumor treatment may be planned.
Publication Information Expand/Collapse
2016
PMid: PMID27325863 | PMC number: PMC5012713
2009
Southwest Oncology Group trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer [PMC2703693; PMID19464730]